Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Women with obesity, with or without type 2 diabetes, will undergo an eight-week, twice-weekly whole-body vibration training program guided by a physiotherapist. Muscle activity around the ankle will be measured during walking and balance tasks using wireless surface electromyography, before and after the training. The study aims to see if diabetes status influences neuromuscular responses and functional outcomes from the vibration intervention. Assessments include walking tests, balance tasks, and muscle activation of the tibialis anterior, soleus, and medial gastrocnemius. The trial is conducted at Pamukkale University and uses a standardized protocol to monitor safety and progress.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Female.
* Aged 18 to 65 years.
* Body mass index (BMI) ≥30 kg/m².
* Willing to participate and provide informed consent.
* For Group 1: Presence of type 2 diabetes mellitus.
* For Group 2: Absence of type 2 diabetes mellitus.

Exclusion Criteria:

* Cardiopulmonary, orthopedic, or neurological conditions that prevent participation in physical activity.
* Congenital musculoskeletal deformities.
* Cognitive impairment that prevents effective communication.
* Presence of osteoporosis or osteopenia.

Where it's running

• Pamukkale University, Faculty of Physiotherapy and Rehabilitation
  Denizli, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: Ummuhan Baş Aslan, Prof.
• Email: umbaslan@pau.edu.tr
• Phone: +902582964295

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

• Clazakizumab for adults with high hsCRP at risk for a heart event

  This study tests whether clazakizumab can lower inflammation and reduce cardiovascular risk in adults with high hsCRP and existing risk factors.

  Recruiting at 32 sites Phase 2 Eli Lilly and Company · Huntsville, Alabama and 45 other locations · NCT07783802

• AI-assisted lifestyle plan vs. tirzepatide for obesity with newly diagnosed type 2 diabetes

  This study tests whether an AI-guided lifestyle program can help overweight adults with newly diagnosed type 2 diabetes lose more weight and improve blood sugar control compared with tirzepatide or standard lifestyle care.

  Recruiting at 5 sites Phase 4 The First Affiliated Hospital of Anhui Medical University · Hefei, Anhui and 4 other locations · NCT07697391

• Long-term test of maridebart cafraglutide for obesity and type 2 diabetes

  This extension study tests whether maridebart cafraglutide remains effective and safe for people with obesity and type 2 diabetes who previously completed a parent trial.

  Recruiting at 45 sites Phase 3 Amgen · Gilbert, Arizona and 44 other locations · NCT07684144

• Tirzepatide in real-world Paraguay for obesity and type 2 diabetes

  This study tests tirzepatide in adults in Paraguay to see how it works for weight loss and blood sugar control in everyday clinical practice.

  Recruiting Phase 4 Las Rías Medical Center · Asunción · NCT07588438

• How GLP‑1 receptor agonists affect unhealthy organ fat in people with chronic kidney disease

  This observational project will test whether taking GLP‑1 receptor agonist medicines changes harmful fat around organs and related inflammation in adults with chronic kidney disease who also have obesity or type 2 diabetes.

  Recruiting Cardenal Herrera University · Valencia, Valencia · NCT07309094

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.